Please wait while the formulary information is being retrieved.
ZALTRAP (AFLIBERCEPT)
- Metastatic colorectal cancer
100 mg/4 mL (25 mg/mL) intravenous solution
- Infuse 4 mg/kg over 60 minute(s) by intravenous route every 2 weeks
200 mg/8 mL (25 mg/mL) intravenous solution
- Infuse 4 mg/kg over 60 minute(s) by intravenous route every 2 weeks
Metastatic colorectal cancer
- Infuse 4 mg/kg over 60 minute(s) by intravenous route every 2 weeks
- None
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Acute arterial thromboembolism
- Gastrointestinal perforation
- Hypertensive crisis
- Nephrotic syndrome
- Posterior reversible encephalopathy syndrome
- Pregnancy
- Thrombotic thrombocytopenic purpura
- Transient cerebral ischemia
Contraindicated
- Angina
- Gastrointestinal fistula
- Hemorrhage
- Hypertension
- Impaired wound healing
- Invasive surgical procedure
- Neutropenic disorder
- New fistula formation involving an internal organ
- Proteinuria
- Severe diarrhea
- Severe infection
- Stomatitis
- Thrombocytopenic disorder
Severe
Moderate
- None
ZALTRAP (AFLIBERCEPT)
- Metastatic colorectal cancer
- Hemorrhage
- Hypertension
- Leukopenia
- Neutropenic disorder
- Palmar-plantar erythrodysesthesia
- Severe diarrhea
- Thrombocytopenic disorder
- Acute abdominal pain
- Diarrhea
- Dyspnea
- Epistaxis
- Fatigue
- General weakness
- Headache disorder
- Proteinuria
- Stomatitis
- Voice change
- Weight loss
More Frequent
Severe
Less Severe
- Angina
- Dehydration
- Gastrointestinal hemorrhage
- Hematuria
- Kidney disease with reduction in GFR
- Pneumonia
- Rectal bleeding
- Thromboembolic disorder
- Transient cerebral ischemia
- Abnormal hepatic function tests
- Anorexia
- Dyschromia
- Hemorrhoids
- Rectal pain
- Rhinorrhea
- Sore throat
- Tooth disorder
- Upper respiratory infection
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute arterial thromboembolism
- Aseptic necrosis of jaw bone
- Cerebrovascular accident
- Gastrointestinal fistula
- Gastrointestinal perforation
- Heart failure
- Impaired wound healing
- Intracranial bleeding
- Nephrotic syndrome
- Posterior reversible encephalopathy syndrome
- Pulmonary hemorrhage
- Thrombotic thrombocytopenic purpura
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
(Ziv)aflibercept
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Ziv-aflibercept (iv)
- Severity Level:
1
- Additional Notes: Fda c; poss fetal risk, embryotoxic in rabbits at 0.3x mrhd, weigh risk-benefit
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Ziv-aflibercept (iv)
Serious adv effects possible, consider treatment benefit vs. risk to infant
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Serious adv effects possible, consider treatment benefit vs. risk to infant |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Ziv-aflibercept
General-Increased risk of dizziness, weight loss. Monitor closely for dehydration/diarrhea.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause serious (possibly fatal) bleeding, including bleeding from the stomach or intestines. It may also rarely cause a hole to open in the stomach or intestines (gastrointestinal perforation). You should not receive this medication if you have any serious bleeding problems.<br /><br />Tell your doctor right away if you have any signs of these serious side effects, including prolonged bleeding from cuts or gums, persistent/frequent nosebleeds, pink/dark urine, unusual/easy bruising, bloody or black/tarry stools, persistent or severe stomach/abdominal pain, vomit that looks like coffee grounds, coughing up blood, shortness of breath, dizziness/fainting, unusual or persistent tiredness/weakness, severe headache. This medication may also cause wounds to heal slowly or poorly. Tell your doctor right away if you have wounds that are not healing well. You should not receive this medication for at least 4 weeks before and after a major surgery and until the wound from the surgery is fully healed.
| Metastatic colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| 0-9 | A-Z |
|---|---|
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
Formulary Reference Tool